Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer
Brief Summary: Primary objective :

To compare the combination of S-1 and oxaliplatin(SOX) to the combination of capecitabine and oxaliplatin(COX) therapy for advanced or metastatic colorectal carcinoma.

Secondary objectives :

1. To evaluate and compare the efficacy (overall survival and response rate) in the two treatment groups.
2. To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.


Options:
A: Arm Label: FOLFIRI +/- Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Drug: CPT-11 (Irinotecan), Drug: 5-FU Bolus, Drug: 5-FU Infusion, Drug: l-LV (dl-LV) | Arm Label: XELIRI +/- Bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: CPT-11 (Irinotecan), Drug: Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Bolus; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Infusion; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: l-LV (dl-LV); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELIRI +/- Bevacizumab
B: Arm Label: FOLFOX4; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil (5-FU), Drug: Leucovorin calcium, Drug: Oxaliplatin | Arm Label: FOLFOX4 + Bv; Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: 5-Fluorouracil (5-FU), Drug: Leucovorin calcium, Drug: Oxaliplatin | Arm Label: XELOX+Bv; Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Capecitabine, Drug: Oxaliplatin | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFOX4 + Bv, XELOX+Bv | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELOX+Bv | Intervention Type: DRUG; Name: 5-Fluorouracil (5-FU); Assigned to Arm(s): FOLFOX4, FOLFOX4 + Bv | Intervention Type: DRUG; Name: Leucovorin calcium; Assigned to Arm(s): FOLFOX4, FOLFOX4 + Bv | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): FOLFOX4, FOLFOX4 + Bv, XELOX+Bv
C: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
D: Arm Label: S-1 and Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 & Oxaliplatin | Arm Label: Capecitabine and Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine & Oxaliplatin | Intervention Type: DRUG; Name: S-1 & Oxaliplatin; Assigned to Arm(s): S-1 and Oxaliplatin | Intervention Type: DRUG; Name: Capecitabine & Oxaliplatin; Assigned to Arm(s): Capecitabine and Oxaliplatin

Answer: D